Mapping the immunopeptidome of seven SARS-CoV-2 antigens across common HLA haplotypes
Open accessPublished version of a preprint
The DOI matches its Crossref record; 56 of the 56 references it cites were found in a registry or an index; none of the 40 sources its claims cite is checked for support yet.
Abstract
Most COVID-19 vaccines elicit immunity against the SARS-CoV-2 Spike protein. However, Spike protein mutations in emerging strains and immune evasion by the SARS-CoV-2 virus demonstrates the need to develop more broadly targeting vaccines. To facilitate this, we use mass spectrometry to identify immunopeptides derived from seven relatively conserved structural and non-structural SARS-CoV-2 proteins (N, E, Nsp1/4/5/8/9). We use two different B-lymphoblastoid cell lines to map Human Leukocyte Antigen (HLA) class I and class II immunopeptidomes covering some of the prevalent HLA types across the global human population. We employ DNA plasmid transfection and direct antigen delivery approaches to sample different antigens and find 248 unique HLA class I and HLA class II bound peptides with 71 derived from N, 12 from E, 28 from Nsp1, 19 from Nsp4, 73 from Nsp8 and 45 peptides derived from Nsp9. Over half of the viral peptides are unpublished. T cell reactivity tested against 56 of the detected peptides shows CD8+ and CD4+ T cell responses against several peptides from the N, E, and Nsp9 proteins. Results from this study will aid the development of next-generation COVID vaccines targeting epitopes from across a number of SARS-CoV-2 proteins. The immune response to the spike protein of SARS-CoV-2 has been relatively well studied, but less is known about other viral proteins. Here, the authors identify immunopeptides from seven structural and non-structural SARS-CoV-2 proteins presented to the immune system by HLA molecules and confirm T-cell responses against some of them in convalescent individuals.
Overview
CoChat Summary
TL;DR
This study used mass spectrometry immunopeptidomics in two B-lymphoblastoid cell lines to map HLA class I and class II peptides derived from seven conserved SARS-CoV-2 proteins (N, E, Nsp1/4/5/8/9), identifying 248 unique viral peptides, over half previously unpublished. T cell assays in convalescent donors confirmed CD4+ and CD8+ responses against several N, E, and Nsp9 peptides, supporting broader T-cell-based vaccine design.
Key findings
- Across stable transfection and direct antigen delivery, 248 unique HLA class I/II-bound SARS-CoV-2 peptides were identified: 71 from N, 12 from E, 28 from Nsp1, 19 from Nsp4, 73 from Nsp8, and 45 from Nsp9; over half were unpublished.
- Stable transfection of BLCLs yielded 181 non-redundant SARS-CoV-2 peptides; direct protein delivery yielded 81 unique peptides. Nsp8 and Nsp9 were efficiently presented, with 78% and 85% sequence coverage, respectively, in the 9004 and 9087 BLCL immunopeptidomes.
- Of 56 tested synthetic peptides, T cell reactivity was detected against several peptides from N, E, and Nsp9. CD4+ responses included nested E57-65/E58-73, Nsp1 88-99/89-97, and Nsp9 45-55/45-59; a dominant CD4+ response to N343-361 occurred in three donors. A CD8+ response was narrowed to N71-85, N77-86, and N77-87.
- Binding prediction assigned 53% (105/200) of PTM-stripped viral immunopeptides as binders to at least one expressed HLA allotype; 43/200 peptides had similarity to human protein-derived peptides (up to two mismatches). Twelve antigen presentation hotspots were identified.
Methods
- Two EBV-transformed B-LCLs (IHW09004 and IHW09087) expressing common HLA class I/II allotypes were used. Antigens were introduced by stable transfection with plasmids encoding N, E, Nsp8, and Nsp9, or by direct electroporation of recombinant N, Nsp1, Nsp4, Nsp5, and Nsp9 proteins.
- HLA class I and class II peptide complexes were immunoaffinity-purified with W6/32 and a mix of SPV-L3/B7/21/LB3.1 antibodies, respectively, then analyzed by LC-MS/MS on a Bruker timsTOF Pro with PASEF. Data were searched with PEAKS Online 10 against human and SARS-CoV-2 proteomes at 5% FDR, with 1% FDR re-testing for viral peptides.
- T cell reactivity was tested using 56 synthetic peptides in pools with PBMCs from 9 convalescent donors collected 12–223 days post-infection; cells were expanded for 10 days, restimulated, and analyzed by intracellular cytokine staining for IFNγ/TNF. Binding predictions used netMHCpan/netMHCIIpan, and results were compared with IEDB.
Limitations
- Stated: T cell validation was limited to nine donors with variable HLA allotypes, and larger cohorts are needed to assess immunodominance. The direct delivery approach may not capture mammalian post-translational modifications if bacterially expressed protein is used, and it directs presentation predominantly to HLA class II; B cells may also be less efficient at cross-presentation.
- Stated: the study does not resolve what determines antigen processing/presentation hotspots, and further work is needed on proteasome processivity, PTMs, and antigen structure.
- Evident from the text: only two B-LCLs were profiled, T cell assays covered only 56 of 248 detected peptides, and no in vivo protection or vaccine efficacy was tested.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
0 Valid · 1 Not valid · 23 Not checked · 77 Own results and interpretations
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The non-structural proteins Nsp8 and Nsp9, which are not currently in focus for vaccine development, are efficiently presented: 78% of the Nsp8 and 85% of the Nsp9 sequences were covered by the 9004 and 9087 BLCL immunopeptidomes.”
§ Mapping the immunopeptidome of seven SARS-CoV-2 antigens across common HLA haplotypes > Results > Characterisation of HLA ligands presented by BLCL transfected with SARS-CoV-2 derived genes
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“We detected an average of 34,164 8- to 12-mer human peptides isolated using the anti-pan class I antibody W6/32 and an average of 76,863 10- to 20-mer peptides per sample isolated using a mix of HLA class II specific antibodies (SPV-L3, B7/21 and LB3.1) with 5% FDR cut-off applied (Fig. 2A).”
§ Mapping the immunopeptidome of seven SARS-CoV-2 antigens across common HLA haplotypes > Results > Characterisation of HLA ligands presented by BLCL transfected with SARS-CoV-2 derived genes
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“We detected an average of 34,164 8- to 12-mer human peptides isolated using the anti-pan class I antibody W6/32 and an average of 76,863 10- to 20-mer peptides per sample isolated using a mix of HLA class II specific antibodies (SPV-L3, B7/21 and LB3.1) with 5% FDR cut-off applied (Fig. 2A).”
§ Mapping the immunopeptidome of seven SARS-CoV-2 antigens across common HLA haplotypes > Results > Characterisation of HLA ligands presented by BLCL transfected with SARS-CoV-2 derived genes
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The presentation of Nsp9-derived ligands was more comparable between both methods.”
§ Mapping the immunopeptidome of seven SARS-CoV-2 antigens across common HLA haplotypes > Results > Comparison of direct delivery and stable transfection approaches
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Collectively, binding prediction to source cell line-specific HLA allotypes confirmed that 53% (105/200) of the detected, PTM-stripped viral immunopeptides were predicted binders to at least one HLA allotype expressed by the cell lines.”
§ Mapping the immunopeptidome of seven SARS-CoV-2 antigens across common HLA haplotypes > Results > Immunopeptidomic profiling of viral antigen presentation
boostedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
45 more claims
Create a free account to see all 101 claims and to verify the 40 references still open.
- It may state two separate claims as one. 41
- Probably not a substantial claim. 20
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Mapping the immunopeptidome of seven SARS-CoV-2 antigens across common HLA haplotypes > Results > Immunogenicity of a subset of detected SARS-CoV-2 peptides
“median with 95% CI is shown (n = 9 donors, mean with SD; right)”
§ Mapping the immunopeptidome of seven SARS-CoV-2 antigens across common HLA haplotypes > Results > Immunogenicity of a subset of detected SARS-CoV-2 peptides
“n = 9 donors, mean with SD; right”
Citations
Cites
A SARS-CoV-2 protein interaction map reveals targets for drug repurposing
Gordon, D. E., Jang, G. M., Bouhaddou, M., Xu, J., Obernier, K., White, K. M., O’Meara, M. J., Rezelj, V. V., Guo, J. Z., Swaney, D. L., et al. (2020) · Nature · doi:10.1038/s41586-020-2286-9 · Cited by 4,405
Data, disease and diplomacy: GISAID's innovative contribution to global health
Elbe, S., & Buckland‐Merrett, G. (2017) · Global Challenges · doi:10.1002/gch2.1018 · Cited by 1,928
SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls
Le Bert, N., Tan, A. T., Kunasegaran, K., Tham, C. Y. L., Hafezi, M., Chia, A., Chng, M. H. Y., Lin, M., Tan, N., Linster, M., et al. (2020) · Nature · doi:10.1038/s41586-020-2550-z · Cited by 1,887
Spike mutation D614G alters SARS-CoV-2 fitness
Plante, J. A., Liu, Y., Liu, J., Xia, H., Johnson, B. A., Lokugamage, K. G., Zhang, X., Muruato, A. E., Zou, J., Fontes-Garfias, C. R., et al. (2021) · Nature · doi:10.1038/s41586-020-2895-3 · Cited by 1,558
The T cell immune response against SARS-CoV-2
Moss, P. (2022) · Nature Immunology · doi:10.1038/s41590-021-01122-w · Cited by 1,235
Selective and cross-reactive SARS-CoV-2 T cell epitopes in unexposed humans
Mateus, J., Grifoni, A., Tarke, A., Sidney, J., Ramirez, S. I., Dan, J. M., Burger, Z. C., Rawlings, S. A., Smith, D. M., Phillips, E., et al. (2020) · Science · doi:10.1126/science.abd3871 · Cited by 1,120
Proteomics of SARS-CoV-2-infected host cells reveals therapy targets
Bojkova, D., Klann, K., Koch, B., Widera, M., Krause, D., Ciesek, S., Cinatl, J., & Münch, C. (2020) · Nature · doi:10.1038/s41586-020-2332-7 · Cited by 1,010 · cited 1×
“Together with the structural N and E proteins, Nsp8 and Nsp9 are among the most highly abundant non-structural proteins detectable from a few hours post infection with continuing expression until at least 24 h post infection 30 .”
A time- and cost-efficient system for high-level protein production in mammalian cells
Aricescu, A. R., Lu, W., & Jones, E. Y. (2006) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444906029799 · Cited by 762
Comparative host-coronavirus protein interaction networks reveal pan-viral disease mechanisms
Gordon, D. E., Hiatt, J., Bouhaddou, M., Rezelj, V. V., Ulferts, S., Braberg, H., Jureka, A. S., Obernier, K., Guo, J. Z., Batra, J., et al. (2020) · Science · doi:10.1126/science.abe9403 · Cited by 747
Using i RT, a normalized retention time for more targeted measurement of peptides
Escher, C., Reiter, L., MacLean, B., Ossola, R., Herzog, F., Chilton, J., MacCoss, M. J., & Rinner, O. (2012) · PROTEOMICS · doi:10.1002/pmic.201100463 · Cited by 600
Cited by
Vaccine Strategies Against RNA Viruses: Current Advances and Future Directions
Hsiung, K. C., Chiang, H.-J., Reinig, S., & Shih, S. (2024) · Vaccines · doi:10.3390/vaccines12121345 · Cited by 26
Kovalchik, K. A., Hamelin, D. J., Kubiniok, P., Bourdin, B., Mostefai, F., Poujol, R., Paré, B., Simpson, S. M., Sidney, J., Bonneil, É., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-54734-9 · Cited by 16
Immunogenicity Prediction with Dual Attention Enables Vaccine Target Selection
Li, S., Tan, Y., Ke, S., Hong, L., & Zhong, B. (2025) · International Conference on Learning Representations · doi:10.48550/arxiv.2410.02647 · Cited by 11
A Primer on Proteomic Characterization of Intercellular Communication in a Virus Microenvironment
Kostas, J. C., Brainard, C. S., & Cristea, I. M. (2025) · Molecular & Cellular Proteomics · doi:10.1016/j.mcpro.2025.100913 · Cited by 4
Chung, S., Knox-Johnson, I. G., Gazzard, S. E., Song, R., Le, N. H., Cullen‐McEwen, L. A., Bertram, J. F., Purcell, A. W., & Braun, A. (2025) · Methods and Protocols · doi:10.3390/mps8030043 · Cited by 2
Self-citation
Metadata
- Authors
- Braun, A., Rowntree, L. C., Huang, Z., Pandey, K., Thuesen, N., Li, C., Petersen, J., Littler, D. R., Raji, S., Nguyen, T. H. O., Jappe Lange, E., Persson, G., Schantz Klausen, M., Kringelum, J., Chung, S., Croft, N. P., Faridi, P., Ayala, R., Rossjohn, J., Illing, P. T., Scull, K. E., Ramarathinam, S., Mifsud, N. A., Kedzierska, K., Sørensen, A. B., & Purcell, A. W.
- Affiliations
- Monash University (AU)
- The University of Melbourne (AU)
- Corresponding author
- Purcell, Anthony W.
- ORCID
- Braun, Asolina
- Rowntree, Louise C.
- Huang, Ziyi
- Pandey, Kirti
- Li, Chen
- Petersen, Jan
- Littler, Dene R.
- Raji, Shabana
- Nguyen, Thi H. O.
- Persson, Gry
- Kringelum, Jens
- Chung, Shanzou
- Croft, Nathan P.
- Faridi, Pouya
- Ayala, Rochelle
- Rossjohn, Jamie
- Illing, Patricia T.
- Scull, Katherine E.
- Ramarathinam, Sri
- Mifsud, Nicole A.
- Kedzierska, Katherine
- Purcell, Anthony W.
- Venue
- Nature Communications
- Published
- 2024-08-30
- Volume
- 15
- Issue
- 1
- Pages
- 7547-7547
- ISSN
- 2041-1723 (ISSN-L)
- PMC
- PMC11364864
- OpenAlex
- W4402044597
- Cited by
- 12
- References
- 56
- Citations by year
- 2026: 5 · 2025: 5 · 2024: 2
- FWCI
- 1.12
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by-nc-nd
- creativecommons.org/licenses/by-nc-nd/4.0 (tdm)
- creativecommons.org/licenses/by-nc-nd/4.0 (vor)
- Locations
- Nature Communications (publishedVersion, cc-by-nc-nd)
- Research Square (submittedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- ORCA Online Research @Cardiff (Cardiff University) (submittedVersion, cc-by-nc-nd)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Minerva Access (University of Melbourne) (submittedVersion, cc-by-nc-nd)
- Funders
- National Psoriasis Foundation (817907)
- Innovationsfonden
- Rebecca L. Cooper Medical Research Foundation (PG2020775)
- Monash University
- Medical Research Council
- National Health and Medical Research Council (2016596, 1194036, 2026357, 1143366, 1173871)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › vaccines and immunoinformatics approaches
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Physical Sciences › Chemistry › Organic Chemistry › Chemical Synthesis and Analysis
- Keywords
- SARS-CoV-2, immunopeptidome, HLA class I, HLA class II, viral peptides, non-structural proteins, nsp9, nsp8, NSP4, Nsp1, envelope protein, nucleocapsid protein, T cell epitopes, CD8+ T cells, CD4+ T cells, COVID-19 vaccines, HLA haplotypes, B-lymphoblastoid cell lines, convalescent patients
- MeSH terms
- COVID-19, SARS-CoV-2, COVID-19 Vaccines, Histocompatibility Antigens Class II, Antigens, Viral, Cell Line, Haplotypes, HLA Antigens, Humans, Peptides, Histocompatibility Antigens Class I, CD4-Positive T-Lymphocytes, CD8-Positive T-Lymphocytes, Epitopes, T-Lymphocyte, Spike Glycoprotein, Coronavirus
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-11-21, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-11-21 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Mapping the immunopeptidome of seven SARS-CoV-2 antigens across common HLA haplotypes. https://app.cochat.ai/papers/10.1038/s41467-024-51959-6
- The paper
- Braun, A., Rowntree, L. C., Huang, Z., Pandey, K., Thuesen, N., Li, C., Petersen, J., Littler, D. R., Raji, S., Nguyen, T. H. O., Jappe Lange, E., Persson, G., Schantz Klausen, M., Kringelum, J., Chung, S., Croft, N. P., Faridi, P., Ayala, R., Rossjohn, J., . . . Purcell, A. W. (2024). Mapping the immunopeptidome of seven SARS-CoV-2 antigens across common HLA haplotypes. Nature Communications. https://doi.org/10.1038/s41467-024-51959-6
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.